D2C7 immunotoxin

DB17540InvestigationalProtein Based Therapies

D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial...

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Also known as: D2C7-immunotoxin · D2C7-IT

Resolves to

Targets

P00533EGFR

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with D2C7 immunotoxin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account